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Using assay-directed fractionation of Conus geogra-
phus crude venom, we isolated -conotoxin GID, which
acts selectively at neuronal nicotinic acetylcholine re-
ceptors (nAChRs). Unlike other neuronally selective
-conotoxins, -GID has a four amino acid N-terminal
tail, -carboxyglutamate (Gla), and hydroxyproline (O)
residues, and lacks an amidated C terminus. GID inhib-
its 7 and 32 nAChRs with IC50 values of 5 and 3 nM,
respectively and is at least 1000-fold less potent at the
11, 34, and 44 combinations. GID also potently
inhibits the 42 subtype (IC50 of 150 nM). Deletion of the
N-terminal sequence (GID1–4) significantly decreased
activity at the 42 nAChR but hardly affected potency
at 32 and 7 nAChRs, despite enhancing the off-rates
at these receptors. In contrast, Arg12 contributed to
42 and 7 activity but not to 32 activity. The three-
dimensional structure of GID is well defined over resi-
dues 4–19 with a similar motif to other -conotoxins.
However, despite its influence on activity, the tail ap-
pears to be disordered in solution. Comparison of GID
with other 4/7-conotoxins which possess an NN(P/O)
motif in loop II, revealed a correlation between increas-
ing length of the aliphatic side-chain in position 10
(equivalent to 13 in GID) and greater 7 versus 32
selectivity.
Neuronal nicotinic acetylcholine receptors (nAChR)1 repre-
sent important targets for the development of novel drugs for
the treatment of pain and various disorders of the central
nervous system (1). To date, eight  and three  subunits
(2–7, 9, 10, 2–4) of the nAChRs have been cloned from
sensory and neuronal mammalian cells (2–4). For the 7 and
9 subunits, it has been shown that they need no additional
subunits to form functional ion channels upon heterologous
expression. All other  subunits, however, require at least the
co-expression of one  subunit, or another  subunit in the case
of 10. Ternary combinations of two different  and one 
subunit or two different  and one  subunit, and even quater-
nary combinations have been described (5, 6). This diversity of
subunit combinations has the potential to generate a wide
range of receptor subtypes with different pharmacological and
functional properties. To help unravel which native neuronal
nAChR subunit combinations are responsible for specific phys-
iological functions, additional selective inhibitors are required.
Conotoxins are small disulfide-rich peptides from the venom
of the predatory marine snails of the genus Conus. These mini-
proteins have proved to be valuable tools for investigating the
structure and function of ligand- and voltage-gated ion chan-
nels. -Conotoxins are competitive antagonists of acetylcholine
(ACh) binding to the nAChR (7). The -conotoxins described so
far are among the most selective inhibitors to be identified (Fig.
1). They are typically 12–18 amino acids long, contain a con-
served Pro in loop I, and are folded by two disulfide bonds
connecting Cys1–Cys3 and Cys2–Cys4. Based on the number of
amino acids between the second and third cysteine residues
(loop I) and the third and fourth cysteine residues (loop II) they
are divided into 3/5, 4/7, 4/6, and 4/3 structural subfami-
lies (8). The 3/5-conotoxins are selective for the muscle-type
nAChR, while most 4/7- and 4/6-conotoxins are selective for
neuronal nAChRs. An exception is the 4/7-conotoxin EI, which
binds to the / interface of the muscle-type nAChR (9). The
4/3-type characterized by ImI is 7-selective (10). The three-
dimensional structures of different neuronal-specific and mus-
cle-specific -conotoxins have been determined by NMR (11–
15) and x-ray structural analysis (16–19). The 4/7-conotoxins
and ImI share similar backbone conformations and a rigid
hydrophobic core (14), suggesting that their different specific-
ities for nAChR subtypes arise from the different amino acid
side-chains projecting from this conserved scaffold.
The 42 nAChRs together with the 7 subtype are the most
abundant nAChRs in mammalian brain. Knockout studies in
mice have revealed an important role for 4 and 2 in pain and
cognition (20) but further investigations of its role are limited
by the lack of 42-selective inhibitors. A primary goal of this
study was to identify new -conotoxins active at the 42
subtype. In this report, we describe the isolation and charac-
terization of 4/7-conotoxin GID. GID possesses a novel four
amino acid N-terminal tail and an Arg in position 12 that
contribute to 42 selectivity. The NMR structure of GID was
determined to define the location of structural features that
contribute to the selectivity of GID.
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EXPERIMENTAL PROCEDURES
Isolation, Purification, and Sequencing of GID
Extraction of Crude Venom—Nine specimens of Conus geographus
were collected from the Great Barrier Reef, Australia. Crude venom
duct contents were extracted with 30% acetonitrile/water acidified with
0.1% trifluoroacetic acid and centrifuged. Soluble material (120 mg)
was lyophilized and stored at 20 °C prior to use.
Isolation and Purification of GID—A portion of the crude venom
extract (40 mg) was fractionated on a semipreparative RP-HPLC col-
umn (10-m C18, Vydac) eluted at 3 ml/min with a linear gradient of
0–80% solvent B over 80 min (solvent A, 0.1% trifluoroacetic acid;
solvent B, 90% acetonitrile, 0.09% trifluoroacetic acid). Inhibition in a
functional nAChR assay (see below) identified an active 1-min fraction
eluting at 21 min (Fig. 2A), which was further purified by RP-HPLC
employing a linear gradient of 0–25% B over 25 or 45 min (5-m C18,
46  250 mm Zorbax or Jupiter columns at 1 ml/min or a SB300 3.5 m
C18, 2.1  50 mm Zorbax column at 0.2 ml/min eluted with solvent A,
0.05% trifluoroacetic acid; solvent B, 90% acetonitrile and 0.045% tri-
fluoroacetic acid). An active peptide detected at 214 nm was collected
and sequenced after reduction and alkylation with maleimide (see be-
low). Venom was further characterized by LC/MS analysis using a
PESciex API QSTAR Pulsar mass spectrometer (m/z 500–2200) to
monitor the eluant from a 5-m C3, 2.1 150 mm Zorbax column eluted
with 0–60% B over 60 min (A, 0.1% formic acid; B, 90% aqueous
acetonitrile, 0.09% formic acid).
Sequencing—The purified peptide (20 pmol) was reduced in the
presence of 10 mM TCEP and 50 mM ammonium acetate, pH 4.5 (37 °C
for 1 h) before alkylating in the added presence of 20 mM maleimide
(37 °C for 1 h). The alkylated peptide was repurified by RP-HPLC prior
to sequence analysis by Edman chemistry on a 492–01 HT model
Procise protein sequencer (see Fig. 1). Stock solutions of 100 mM Tris(2-
carboxyethyl)-phosphine hydrochloride (Pierce), and maleimide (Al-
drich) were prepared in 0.1 M ammonium acetate pH 4.5 and in 10%
acetonitrile, respectively, and stored at 20 °C.
Peptide Synthesis
GID and analogues were manually assembled by Boc chemistry,
deprotected, and cleaved from resin as described previously (21). Amino
acid side-chain protection was as follows: Arg (Tos), Asn(Xan), Asp(O-
cHex), Cys(pMeBzl), Gla(OcHex), His (DNP), Hyp(Bzl), and Ser(Bzl).
Linear peptides were manually assembled on t-Boc-cysteine-Pam resin,
(0.75 mmol substitution/g; Applied Biosystems, Foster City, CA). Dou-
ble couplings were used where necessary to achieve coupling efficiencies
of 99.5%. HPLC-purified reduced peptides (50 M) were oxidized in
100 mM ammonium bicarbonate at pH 7.5–8 with stirring for 24–48 h
at 23 °C. The oxidized peptides were purified by preparative RP-HPLC.
The major oxidized product was co-injected with native GID in a 2:1
ratio. Peptides were quantified initially in triplicate by amino acid
analysis (22), then subsequently by RP-HPLC using an external refer-
ence standard for each peptide.
Functional Characterization of GID
RNA Preparation—Plasmids containing cDNA encoding rat 3, 4,
7, 2, and 4 nAChR subunits were provided by J. Patrick (Baylor
College of Medicine, Houston, TX) and subcloned into the oocyte expres-
sion vector pNKS2 (23). cDNAs for the mouse 1, 1, , and  subunits
of the muscle nAChR were provided by Dr. V. Witzemann (Max-Planck
Institute for Medical Research, Heidelberg, Germany). Capped cRNAs
were synthesized from linearized plasmid cDNAs using the Message
Machine Kit (Ambion, Austin, TX).
Expression in Xenopus Oocytes—Oocytes were prepared as previ-
ously described (24), injected with 50 nl of cRNA (5–50 ng/l), and kept
at 19 °C in ND96 (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and
5 mM Hepes at pH 7.4) supplemented with 50 mg/liter of gentamycin
(Sigma Chemical Co.).
Two Electrode Voltage-Clamp Recording—Two electrode voltage-
clamp recordings were performed in oocytes 2–10 days after cRNA
injection at a holding potential of 70 mV. Pipettes were pulled from
borosilicate glass (Harvard Apparatus Ltd., Kent, England) and filled
with 3 M KCl. Resistances were below 1 M. Membrane currents were
recorded using a two electrode virtual ground circuit on a GeneClamp
500B amplifier (Axon Instruments Inc., Union City, CA), filtered at 200
Hz and digitized at 1 kHz using a Digidata 1322A interface and v8.2
Clampex software (Axon Instruments Inc.). Recordings were performed
in ND96 at room temperature. 1 M ACh (Sigma) was used to activate
44 and 11 nAChRs, 100 M ACh was used to activate 32,
34, and 42 nAChRs, and 100 M nicotine (Sigma) was used to
activate 7 nAChR. The perfusion medium was manually switched
between ND96 with or without agonist using a Valve Driver II (General
Valve Corporation, Fairfield, NJ). A fast and reproducible solution
exchange (300 ms) for agonist application was achieved using a 50-l
funnel-shaped oocyte chamber combined with a fast solution flow (150
l/s) fed through a custom-made manifold mounted immediately above
the oocyte. ACh pulses were applied for 2 s at 6-min intervals. After
each application, the cell was superfused for 1 min with agonist-free
solution, and the flow was then stopped for 5 min before agonist solu-
tion was re-introduced. Peptide was applied when responses to three
consecutive agonist applications differed by less than 10%. After the
1-min agonist washout step was stopped, 5.5 l of a 10-fold concen-
trated peptide solution were pipetted directly into the static bath, mixed
by repeated pipetting, and incubated for 5 min prior to application of
agonist. Addition of toxin directly to the recording chamber conserved
material and avoided potential adhesion of the toxin to tubing surfaces.
To obtain estimates of potency, dose-response curves were fitted to the
data by the equation percent response 100/{1 ([toxin]/IC50)
nH} using
Prism software (GraphPad v 3.0 for Macintosh, San Diego, CA). To
obtain estimates of toxin washout kinetics, agonist responses were
measured at 2-min intervals under constant superfusion. For toxin
application, oocytes were superfused for 1 min before a 1-min incuba-
tion with the toxin followed by the next agonist application.
NMR Solution Structure of GID
Sample Preparation—Samples for 1H NMR measurement contained
2.5 mM synthetic GID in 90% H2O, 10% D2O or 100% D2O at pH 2.8.
NMR Spectroscopy—Spectra were obtained on a Bruker DMX 750
spectrometer at 280 and 287 K. All spectra were acquired in phase-
sensitive mode using TPPI (25). The homonuclear spectra recorded
included double quantum filtered DQF-COSY (26), TOCSY (27) using a
MLEV17 spin lock sequence (28) with an isotropic mixing time of 80 ms;
ECOSY (29), and NOESY (30) with mixing times of 150 and 350 ms. In
DQF-COSY and ECOSY experiments, the water resonance was sup-
pressed by low power irradiation during the relaxation delay (1.5 s). For
the TOCSY and NOESY experiments, water suppression was achieved
using a modified WATERGATE sequence (31). Two-dimensional spec-
tra were generally collected over 4096 data points in the f2 dimension
and 512 increments in the f1 dimension over a spectral width corre-
sponding to 12 ppm. For identification of slowly exchanging amides, a
series of one-dimensional and TOCSY spectra were run immediately
after dissolving the sample in D2O. All spectra were processed on a
Silicon Graphics workstation using XWINNMR (Bruker). The f1 dimen-
sion was zero-filled to 2048 real data points with the f1 and f2 dimen-
sions being multiplied by a sine-squared function shifted by 90° prior to
Fourier transformation. Processed spectra were analyzed and assigned
using the program XEASY (32). Spectra were assigned using the se-
quential assignment protocol (33). The process was facilitated, in part,
FIG. 1. Comparison of -GID and related neuronally active
-conotoxins. A, sequence and selectivity of neuronally active -cono-
toxins. A motif (NN(O/P)) commonly found in the second loop of 4/7-
conotoxins is marked in gray. Asterisks indicate C-terminal amidation.
Sulfated Tyr are underlined, , -carboxyglutamic acid, and O, hy-
droxyproline. B, sequences of GID analogues investigated in this study.
Mutated residues are marked in gray. Selectivity determined from
oocyte studies except for EpI, which was determined from studies in
neurons.
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using the automatic assignment program NOAH, which is part of the
DYANA package (34).
Structure Calculations—Cross-peaks in NOESY spectra recorded in
90% H2O, 10% D2O with mixing times of 350 and 150 ms were inte-
grated and calibrated in XEASY, and distance constraints were derived
using DYANA. Backbone dihedral angle restraints were derived from
3JHNH coupling constants measured from line shape analysis of an-
tiphase cross-peak splitting in the DQF-COSY spectrum. Angles were
restrained to 120° 	 30 for 3JHNH  8.5 Hz and to 60° 	 30 for
3JHNH  5 Hz. Stereospecific assignments of -methylene protons and
1 dihedral angles were derived from 3J coupling constants, meas-
ured from ECOSY spectra, in combination with NOE peak intensities
(35). Slowly exchanging amide protons identified by D2O exchange
experiments were used in conjunction with preliminary structures to
determine hydrogen bonds. In cases where hydrogen bonds could be
determined and unambiguously assigned, appropriate distance re-
straints were included in the subsequent calculations. Preliminary
structures were calculated using a torsion angle simulated annealing
protocol within DYANA. Final structures were calculated using simu-
lated annealing and energy minimization protocols within CNS version
1.0 (36). The starting structures were generated using random , 
dihedral angles and energy-minimized to produce structures with the
correct local geometry. A set of 50 structures was generated by a torsion
angle simulated annealing protocol (37, 38). This protocol involves a
high temperature phase comprising 4000 steps of 0.015 ps of torsion
angle dynamics, a cooling phase with 4000 steps of 0.015 ps of torsion
angle dynamics during which the temperature was lowered to 0 K, and
finally an energy minimization phase comprising 5000 steps of Powell
minimization. Structures consistent with restraints were subjected to
further molecular dynamics and energy minimization in a water shell,
as described by Linge and Nilges (39). The refinement in explicit water
involves the following steps. First heating to 500 K via steps of 100 K,
each comprising 50 steps of 0.005 ps of Cartesian dynamics. Second,
2500 steps of 0.005 ps of Cartesian dynamics at 500 K before a cooling
phase where the temperature was lowered in steps of 100 K, each
comprising 2500 steps of 0.005 ps of Cartesian dynamics. Finally, the
structures were minimized with 2000 steps of Powell minimization.
Structures were analyzed using Promotif and Procheck (40, 41).
RESULTS
Isolation and Chemical Characterization of GID
Isolation and Sequence of GID—In the search for new -cono-
toxins, the crude venom of C. geographus was screened for
inhibition of agonist-evoked currents at muscle nAChR and
different combinations of neuronal nAChR subunits (32,
34, 42, 44, and 7) heterologously expressed in Xenopus
oocytes. Crude venom (50 g protein/ml by BCA assay) caused
100% block of the 32 and 7 nAChR subtypes and had weak
activity at 42. LC/MS analysis of the crude venom, and MS
analysis of individual fractions, confirmed the presence of the
known muscle selective -conotoxins GI, GIA, and GIB, while
GII and the neuronally active GIC were not found (Fig. 2, A and
B). Thus this pool of C. geographus crude venom appeared to
contain a novel neuronally active -conotoxin. Inhibitory activ-
ity at the 32 and 7 subtypes was used to guide fraction-
ations of the crude venom, yielding a single component of
2184.9 Da (Fig. 2, A and B) that inhibited 32, 7, and 42
nAChR subtypes. Edman sequencing of the reduced and alky-
lated peptide, together with mass spectrometry evidence for
the -carboxyglutamic acid (), revealed a new 4/7-conotoxin
sequence IRDCCSNPACRVNNOHVC (Fig. 1), that we named
-GID following the nomenclature proposed by Olivera and
co-workers (8). The identical sequence was also identified in
Conus tulipa crude venom.2 GID possesses an NN(P/O) motif
also found in -conotoxins EpI, PnIA, and PnIB (Fig. 1A) but
additionally has a four residue N-terminal tail. GID is the first
non-amidated, neuronally active -conotoxin identified.
Chemical Synthesis of GID and Analogues—To characterize
GID and investigate the influence of the N-terminal tail on its
functional properties, GID and an analogue missing the four
N-terminal amino acids (GID
1–4) were synthesized (Fig. 1B).
A single point mutant, [R12A]GID, was also synthesized to
investigate the influence of the unusual charged residue in this
position on nAChR selectivity. All peptides were purified to
95% purity determined by HPLC and MS analysis. Oxidized
synthetic GID co-eluted with native GID on reversed-phase
HPLC (Fig. 2C), and both peptides had identical masses (mo-
noisotopic masses: observed native, 2184.9; observed synthetic,
2184.9; theoretical, 2184.9).
Functional Characterization of GID—Both native and syn-
thetic GID blocked 32 and 7 nAChRs receptors expressed in
Xenopus oocytes with equal potency (data not shown). Syn-
thetic GID was used in further experiments to determine the
potency and subtype selectivity of GID at neuronal 32, 34,
42, 44, and 7, and muscle 12 nAChRs expressed in
oocytes. The concentration response curves for GID are shown
in Fig. 4A, and IC50 values and Hill slope coefficients are
summarized in Table I. GID was most potent at 32 and 7
nAChR subtypes, with IC50 values of 3 and 5 nM, respectively
(Fig. 3A). The activity at the 34, 44, and muscle nAChRs
was at least 1000-fold less. This potency and selectivity profile
of GID is somewhat reminiscent of -conotoxin PnIA and
[A10L]PnIA (42, 43). In contrast to these peptides, however,
GID also showed activity at the 42 subtype (IC50 150 nM).
Despite several sequence similarities in the second loop, no
42 activity was found for [A10L]PnIA (42) at 3 M (Fig. 3B).
Influence of the N-terminal Tail and Arg12 on Subtype Selec-
tivity—To identify which structural determinants contribute to
GID selectivity, the roles of the N-terminal tail and the basic
residue Arg12 were investigated. Deletion of the four N-termi-2 L. Thomas and R. J. Lewis, unpublished data.
FIG. 2. Isolation and synthesis of -GID. A, total ion chromato-
gram of C. geographus crude venom extract. The arrow indicates -GID.
A reconstructed molecular mass spectrum of GID is shown in the inset.
B, purification of GID by HPLC. C, coelution of native and synthetic
GID. Synthetic GID (sGID) and native (nGID) were co-injected in a 2:1
ratio and analyzed by HPLC. Retention time (38.3 min) and peak width
was the same for synthetic, native, and the co-injected peptides.
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nal amino acids of GID reduced the activity of the peptide at
the 42 combination by 4-fold (Fig. 3B). Interestingly,
GID
1–4 (1–10 M) caused only a partial block (40%) of 42
receptors, indicating that the tail of GID was required for full
antagonist activity at this subtype combination (no partial
agonist activity was detected with this truncated analogue,
data not shown). However, potency at the 7 and 32 sub-
types was little influenced by removal of the four N-terminal
residues. Activity of [R12A]GID at the 42 and 7 subtype
was reduced 10-fold compared with GID, whereas activity at
the 32 subtype was little affected (Fig. 3, B–D). An analogue
in which the four N-terminal amino acid residues of [R12A]GID
were removed ([R12A]GID
1–4) did not cause any inhibition of
the 42 receptor at 3 M (data not shown).
Influence of the N-terminal Sequence on the Off-rate Kinet-
ics—Inhibition of the 42 nAChR by GID and its analogues
was rapidly reversible, with at least 90% recovery of responses
seen after 2 min (data not shown). However, recovery of the
32 and 7 subtypes from GID block was significantly slower,
requiring 10 and 15 min, respectively (Fig. 4, A and C). In
contrast, inhibition of both 32 and 7 receptors by GID
1–4
was reversed after a 2-min washout (Fig. 4, B and D). Recov-
ery from block by [A10L]PnIA, which does not have an N-
terminal tail, was rapid at the 32 subtype but slow at the 7
subtype (data not shown).
Structural Characterization of GID
NMR Assignments—All spectral data on GID were recorded
in either 90% H2O, 10% D2O or 100% D2O. Spectra recorded at
287 K were primarily used for assignments, while spectra
measured at other temperatures were used to resolve
ambiguities.
Structure Determination and Analysis—Analysis of the
350-ms NOESY spectrum (750 MHz, 287 K) using the program
XEASY allowed the assignment of each spin system to a spe-
cific amino acid. All non-intraresidual peaks were subsequently
assigned both manually and using the NOAH automatic as-
signment within the DYANA program package. Interproton
distance restraints were derived from the NOE intensities and
used in structure calculations using a torsion angle simulated
annealing protocol within DYANA. Preliminary structures
were analyzed to resolve spectral ambiguities and to facilitate
the introduction of new restraints. A set of restraints consisting
of 183 NOE-derived distances and 15 dihedral angle restraints
was used in the final calculations. These restraints included 82
sequential, 35 medium range, 10 long range, and 56 intraresi-
due distances, 6  angle restraints (Cys5, Cys6, Arg12, Val3,
His17, and Cys19), and 9 1 angle restraints (Cys
5, Cys6, Asn8,
Cys11, Val13, Asn14, His17, Val18, and Cys19). Side-chain angle
restraints were derived on the basis of coupling constants and
NOE intensities from a 150 ms NOESY spectrum. There were
also four restraints included for two hydrogen bonds identified
in preliminary structures. In the final round of structure cal-
culations, these restraints were used to calculate a family of 50
structures, using a torsion angle simulated annealing (37, 38)
protocol within CNS version 1.0 (36). Structures consistent
with the restraints were subjected to further molecular dynam-
ics and energy minimization in a water shell.
Secondary Structure—The differences between the H chem-
ical shifts of GID and random coil values (44) are shown in Fig.
5. A negative secondary shift (upfield) for several residues
indicates that GID contains helical structural elements. The
longest uninterrupted region of negative secondary shifts is
TABLE I
Inhibition of nAChR currents by -GID and analogues
IC50 values (nM) and Hill slopes (nH) for inhibition of agonist-evoked
current through 32, 42, and 7 subtypes expressed in Xenopus
oocytes are shown.
-Conotoxin 32 42 7
GID 3.1 (1.16) 152 (1.13) 4.5 (1.06)
GID
1–4 4.6 (1.07) 670 (1.16) 5.5 (1.15)
[R12A]GID 10 (1.14) 2000 (0.86) 48 (1.26)
FIG. 3. Comparison of subtype selectivity and activity of -GID
and its analogues at nAChRs expressed in Xenopus oocytes.
Oocytes were injected with cRNA encoding the indicated nAChR sub-
units and voltage clamped 2–10 days after injection. Responses to ACh
or nicotine (for 7) after a 5-min incubation in the presence of peptide
are shown as percentage of control responses. Error bars are S.E. and
n  3–5 for each data point. A, subtype selectivity of GID. Comparison
of inhibition by GID and its analogues at 42 (B), 32 (C), and 7 (D)
nAChRs. IC50 values and Hill slope coefficients are summarized in
Table I.
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observed for residues 9–13, suggesting that this region forms a
well-defined helix.
Disulfide Connectivity—The amino acid sequence of GID in-
cludes four cysteine residues that are involved in two disulfide
bonds. Initially, the connectivities of the disulfide bonds were
unknown but were assumed to be identical to PnIA on the basis
of sequence similarities. Thus, the pairing of the disulfides was
assumed to be 5–11 and 6–19 (the globular conformation). To
test the validity of this assumption, in addition to calculations
with the globular connectivity, structures were calculated with
the other two possible disulfide connectivities, 5–6, 11–19
(beads conformation), and 5–19, 6–11 (ribbon conformation).
The resultant structures for the beads and ribbon isomers
clearly violated the experimental data with the average target
function from DYANA significantly higher than observed for
the globular conformation. The beads and ribbon conformations
had target functions of 17.45 and 13.44, respectively, compared
with 0.16 for the globular conformation. Structures were also
calculated without S–S restraints, and the average target func-
tion was 6.94. Analysis of the S-S distances in these structures
revealed Cys5–Cys11 was the most likely connectivity. The next
most likely bond was between Cys6–Cys19; however, the dis-
tance between Cys5–Cys19 was not significantly different. In
summary, the structure calculations with and without the di-
sulfide bonds confirmed that GID adopted the globular confor-
mation, and thus had the same disulfide bond pairings as other
-conotoxins.
Description of the Three Dimensional Structure of GID—A
family of the 20 lowest NOE energy structures was chosen from
the final set of 50 structures to represent the solution structure
of GID. The statistics for these 20 structures, which had no
distance violations greater than 0.2 Å and no dihedral angle
violations greater than 3.0°, are given in Table II. The struc-
tures were well defined with the exception of the N-terminal
tail, which had few experimental restraints defining this re-
gion. The mean RMSD over residues 4–19 was 0.34 	 0.17 Å
for the backbone atoms and 1.43 	 0.32 Å for the heavy atoms.
The family of structures obtained superimposed over the back-
bone atoms of residues 4–19 is shown in Fig. 6A. The ribbon
representation of the lowest energy structure is shown in Fig.
6B. Analysis of the backbone angles reveals that 85% of the
residues lie in the most favorable regions of the Ramachandran
plot, 14% are in the additionally allowed region, 0.5% in the
generously allowed region, and 0.5% in the disallowed region.
The residues in the generously allowed and the disallowed
regions correspond to Asp3 and Ile1, respectively, both in the
poorly defined N-terminal tail.
The solution structure of GID was determined to be a highly
compact globular structure consisting of a central region of
-helix and -turns at both the N and C termini. The -helix
comprises residues 9–13 and has two turns. H-bonds between
Asn8(O)–Cys11(HN) and Pro9(O)–Val13(HN) were deduced from
analysis of preliminary structures and slow exchange data and
were explicitly included in the structure calculations. At the N
terminus, the poor definition of residues 1–3 may be associated
with flexibility of this region in solution. Analysis with PRO-
MOTIF reveals that residues 5–8 are involved in a type I
-turn, while residues 15–18 are involved in a type II -turn in
7 of 20 final structures.
A surface representation of GID illustrates a distinct hy-
drophobic face (Fig. 7A) comprising residues Pro9, Ala10,
Val13, Hyp16, and Val18. The hydrophilic residues on the
surface include Ser7, Asn8, Asn14, and Asn15. There are also
four charged residues on the surface of the molecule. Three
(Arg2, Asp3, and Gla4) are part of the disordered N-terminal
FIG. 4. Washout kinetics of GID and GID1–4 from 32 and
7 nAChRs. Xenopus oocytes expressing the 32 (A and B) or 7 (C
and D) nAChR subtypes were stimulated with 1-s pulses of ACh or
nicotine (in the case of 7) applied at 2-min intervals. Oocytes were first
perfused for one more minute with ND96 solution, then incubated with
toxin for 1 min in a static bath, before recommencing agonist applica-
tions during superfusion. Experiments were repeated three times with
similar results. Note that at short incubation times GID is less potent
than GID
1–4, indicating that removal of the N-terminal tail increased
on-rate kinetics as well as accelerating the off-rate kinetics.
FIG. 5. H chemical shift differences of -GID from random
coil values.
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tail. The fourth (Arg12) is situated adjacent to the hydropho-
bic face.
DISCUSSION
Using functional nAChR assay-guided fractionation, we iso-
lated -conotoxin GID from the crude venom of C. geographus.
-GID is the sixth -conotoxin and the second neuronally active
-conotoxin isolated from this species (8, 45), showing the im-
portance of -conotoxins targeting both muscle and neuronal
nAChRs for prey capture. GID appears to replace GIC in this
pool of C. geographus venom. The sequence of GID differs from
previously described -conotoxins in a number of regards. The
most striking is the novel N-terminal tail comprising four
amino acids (Ile1, Arg2, Asp3, Gla4) including the post-transla-
tionally modified -carboxyglutamic acid (Gla). An examina-
tion of the pre-pro regions of -conotoxins from the SWISS-
PROT data base reveals that most conopeptide precursor
sequences contain Arg-Arg, Lys-Lys, Gln-Arg, Lys-Arg, or Arg-
Asp motifs as the cleavage site. For example, ImIIA utilizes
Ile-Arg-Asp-Tyr (accession number Q9U619) to leave a Tyr at
position 1 in the mature conopeptide. Since the Arg-Asp cleav-
age site is not utilized in GID, it appears that the -carboxyl-
ation of Glu4 in GID inhibits this cleavage site, allowing the
N-terminal tail to survive in the venom. GID is the first -cono-
toxin to utilize a hydroxyproline residue, despite its widespread
use in other classes of conotoxins, and is the first neuronally
active -conotoxin with a non-amidated C terminus.
Several neuronally active -conotoxins have been identified
that have nanomolar potency for only the 32 (MII, GIC),
34 (AuIB), or 7 (ImI) receptors expressed in Xenopus oo-
TABLE II
Geometric and energy statistics for the 20 final structures of -GID
RMSD from experimental restraints
Interproton distances (Å) 0.036 	 0.001
Dihedral angles (deg) 0.28 	 0.26
RMSD from idealized geometry
Bonds (Å) 3.90  103 	 0.0002
Angles (deg) 0.58 	 0.02
Impropers (deg) 0.51 	 0.03
Energies (kcal mol1)
Etotal 601 	 37.2
ENOE 10.9 	 1.1
Ecdih 0.13 	 0.23
Evdw 16.9 	 5.9
Ebond  Eangle  Eimproper 36.1 	 3.17
Pairwise RMSD for backbone atoms (N,C,C) (Å)
Residues 4–19 0.34 	 0.17
Pairwise RMSD for heavy atoms (Å)
Residues 4–19 1.43 	 0.32
Number of NOE derived inter-residual distance restraints
Sequential 82
Medium range 35
Long range 10
Intraresidue 56
Total 183
Number of dihedral angle restraints
Phi () 6
Chi1 (1) 9
Total 15
Ramachandran plot (%)
Favorable region 85
Additionally allowed 14
Generously allowed 0.5
Disallowed 0.5
FIG. 6. The three-dimensional structure of -GID. A, a family of
20 GID structures superimposed over the backbone atoms of residues
4–19. The disulfides are shown in red and the N and C termini are
labeled. B, secondary structure of GID showing the -helix, two  turns
between residues 4–7 and 14–17, and the tail region. The N and C
termini are labeled. The coordinates for -GID have been deposited
with the Research Collaboratory for Structural Bioinformatics Protein
Data bank (PDB 1MTQ).
FIG. 7. Comparison of the surfaces of -GID (A) and PnIA (B).
Two orientations (rotated 180° around the y-axis) are shown for each
molecule superimposed over the -helical residues. Negatively and
positively charged residues are shown in red and blue, respectively (the
His is assumed to be uncharged at physiological pH). Hydrophobic
residues are shown in green, and hydrophilic residues are in gray.
Cysteine residues involved in disulfide bonds are shown in yellow. Note
a common hydrophobic patch comprising Pro6, Pro7, Ala10, and Pro13 in
PnIA, and Pro9, Ala10, Val13, and Hyp16 in GID.
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cytes (10, 45, 46, 47) (Fig. 1). Other -conotoxins such as PnIA
and PnIB inhibit both the 7 and 32 subtypes with nanomo-
lar potencies, with PnIA being 32 selective and PnIB being
7 selective (42, 43). GID also has low nanomolar potency at
these two nAChR subtypes, but additionally targets the 42
receptor at nanomolar levels. Thus GID has structural features
that allow it to recognize a broader range of nAChR binding
sites than other -conotoxins, making it a versatile tool for
structure-activity studies at the ACh binding site. Comparison
of its structure with those of more “specialized” -conotoxins
may reveal the critical determinants for subtype selectivity.
The ACh binding site has been localized at the interface of an
-subunit ( face) and the respective non- subunit (or  face
in case of the 7 nAChRs) (48–50). To date, there is limited
information on the binding mode of neuronally active -cono-
toxins and the factors that determine subtype selectivity. In a
study to determine the direct interactions between amino acids
of the 7 receptor and -conotoxin ImI, Quiram et al. (49) found
that the two exposed loops of the peptide interact with different
subunits of the 7 receptor, thus bridging the interface be-
tween two adjacent subunits. However, a similar mode of bind-
ing was not found for PnIB (51). Instead, the key bioactive
residues of this peptide form a localized hydrophobic patch that
appears to interact mostly with the  face of the 7 binding
site. Various neuronally active -conotoxins might have
evolved that have one or more attachment points and target
different microdomains that overlap the ACh binding site on
nAChRs (51). Therefore, it might be useful to further subgroup
the neuronally active -conotoxins based on their subunit spec-
ificity and sequence similarity in order to compare structures
that are likely to have similar binding modes.
The three-dimensional solution structure of -conotoxin GID
reveals that it is a well defined molecule, with a backbone
RMSD over residues 4–19 of 0.34 Å; however, residues 1–3 are
completely disordered. The side-chains are well defined, with
the exception of Arg2, Gla4, and Arg12. The core of the molecule
is occupied by the cysteine residue side-chains, whereas the
side-chains of the remaining residues are solvent-exposed. The
NMR structure of GID was compared with the crystal structure
of PnIA (17), an -conotoxin with the same global fold and
related activity at 7 and 32 (Fig. 7B). Superimposition of
the -helical backbone residues of GID with PnIA gives an
RMS deviation of 0.29 Å. This similarity is evidence that 4/7-
conotoxins utilize the same highly conserved, well-defined
backbone structure to present a range of different side-chains
for interaction with specific nAChRs.
Charge distribution appears to be an important factor that
determines nAChR selectivity, with neuronal specific -cono-
toxins being neutral or negatively charged, and muscle-specific
-conotoxins having a net positive charge (52). For example,
PnIA contains a single negatively charged residue, Asp14,
which together with a positive N terminus and neutral, ami-
dated C terminus results in a net charge of zero. At physiolog-
ical pH, GID has four charged residues including two positive
(Arg2 and Arg12) and two negatively charged residues (Asp3
and Gla4). Combined with balancing positive and negatively
charged termini (unlike most other conotoxins GID contains no
amidated C terminus) the net charge is close to zero. A com-
parison of the surfaces of GID and PnIA shows that both
molecules have a similar hydrophobic patch on one face of the
molecule. This patch includes amino acid residues Pro6, Pro7,
Ala10, and Pro13 in PnIA (Fig. 7B), and the corresponding
residues Pro9, Ala10, Val13, and O16 in GID (Fig. 7A). A similar
cluster of hydrophobic residues (Leu5, Pro6, Pro7, Ala9, and
Leu10) has been shown to be important for the high affinity
binding of PnIB to the 7 receptor (51). Exchanging Ala with
Leu at position 10 in PnIA ([A10L]PnIA) enhanced 7 and
reduced 32 potency, suggesting that a long aliphatic side-
chain in this position favored 7 selectivity (42, 43). In support,
the 4/7-conotoxin GIC has a Gly in position 10 and is a potent
32 inhibitor (45) (see Table III). GID, which has similar
potency at both 7 and 32 receptors, has an intermediate
length side-chain (Val13) in the equivalent position to Ala and
Leu. Taken together, it appears that the length of the side-
chain in position 10 (or position 13 in GID) of these 4/7-
conotoxins correlates with their selectivity for 7 or 32 re-
ceptors: the longer the aliphatic side-chain the more 7-
selective and less 32-selective the peptides become (Table
III).
The neighboring amino acid residues in positions 9 and 11
also seem to contribute to this selectivity: Arg12 of GID (equiv-
alent to Ala9 of PnIA), contributes to 7 selectivity, since re-
placing it with an Ala reduced 7 activity by 10-fold without
affecting activity at the 32 receptor. In contrast, Asn11 may
contribute more to 32 versus 7 selectivity, since
[N11S]PnIA was 24-fold less active at the 32 combination
but only 7-fold less active at the 7 subtype as compared with
PnIA. Likewise, PnIB, which has a Ser in position 11, was
20-fold less active at 32 receptors but only 5-fold less active
at the 7 nAChR than [A10L]PnIA (43). Activity at 7 was
little altered in the Asn12Ala and Pro13Hyp analogues of PnIB
(51). However, their conservation in most 4/7-conotoxins sug-
gests they have evolved as a structurally important motif. As
positions 14 and 15 in PnIB also had little influence on affinity
(51), it appears that the side-chains of the first three N-termi-
nal residues in loop II of these 4/7-conotoxins play a key role
in determining potency and selectivity at 32 and 7
subtypes.
GID contains a unique N-terminal tail comprising four
amino acids. Removal of these residues did not affect activity at
7 and 32 subtypes but strongly reduced block at the 42
subtype, turning GID into a partial inhibitor at this receptor.
These results suggest that N-terminal residues outside the
cysteine framework can contribute to 42 activity. However,
this N-terminal motif is not essential for full inhibition of 42,
since GIC is a full inhibitor of the 42 receptor with an IC50
value of 300 nM (45). The reduced times to washout of GID
1–4
from the 7 and 32 receptors suggest that the N-terminal
TABLE III
Comparison of loop II consensus sequences for selected 4/7-conotoxins and analogues
IC50 values and selectivity at 7 and 32 subtypes expressed in Xenopus oocytes are reported.
-Conotoxin 32 7 32/7 Consensussequence Reference
nM nM
GIC 1.1 n.d. — CAGNNQ (45)
PnIA 9.6 252 0.04 CAANNP (43)
[R12A]GID 10 48 0.2 CAVNNO present study
GID 3.1 4.5 0.7 CRVNNO present study
[A10L]PnIA 99 12.6 7.9 CALNNP (43)
PnIB 1970 61 32 CALSNP (43)
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tail can stabilize the binding of GID to 7 and 32 receptors,
presumably by interacting with residues near the ACh binding
pocket that are not accessible to smaller -conotoxins. The
reduced activity of [R12A]GID at the 42 receptor indicates
that Arg12 in loop II also contributes to GID block of 42. Thus
GID reveals novel features contributing to -conotoxin binding
to the 42 receptor. Improving the structural stability of the
N-terminal tail in GID or adding it to other -conotoxins pro-
vides new avenues for the development of 42 selective
inhibitors.
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